SNGX - Soligenix receives $1.5M grant advancing COVID-19 vaccine development

National Institute of Allergy and Infectious Diseases awarded Soligenix (SNGX) a Direct to Phase II Small Business Innovation Research ((SBIR)) grant of ~$1.5M for supporting, manufacturing, formulation and characterization of COVID-19 and EVD vaccine candidates in conjunction with the CoVaccine HT adjuvant.The awarded grant enables detailed immunogenicity evaluation of CoVaccine in the presence of either the SARS-CoV-2 Spike protein antigen or the Zaire ebolavirus glycoprotein antigen in both mice and non-human primates, and will significantly enhance both vaccine programs."This SBIR grant award will further advance our studies with the CoVaccine adjuvant, as well as our CiVax and filovirus vaccine programs," president & CEO Christopher J. Schaber commented.Soligenix shares up 3.7% premarket.

For further details see:

Soligenix receives $1.5M grant advancing COVID-19 vaccine development